Who are LONCASTUXIMAB TESIRINE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Uplizna, BLINATUMOMAB, Blincyto, UPLIZNA, REZ, IL-2 pre-treated CD19 cells.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/loncastuximab-tesirine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

LONCASTUXIMAB TESIRINE — Competitive Intelligence Brief

LONCASTUXIMAB TESIRINE (LONCASTUXIMAB TESIRINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibody-Drug Conjugate (ADC). Area: Oncology.

marketed Antibody-Drug Conjugate (ADC) CD19 Oncology Antibody drug conjugate Live · refreshed every 30 min

Target snapshot

LONCASTUXIMAB TESIRINE (LONCASTUXIMAB TESIRINE). Loncastuximab tesirine is an ADC that targets CD19 on B-lineage cells, internalizes, and releases a cytotoxic agent to induce cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
LONCASTUXIMAB TESIRINE TARGET	LONCASTUXIMAB TESIRINE		marketed	Antibody-Drug Conjugate (ADC)	CD19	2021-01-01
Uplizna	INEBILIZUMAB	Viela Bio	marketed	CD19-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD19	2020-01-01
BLINATUMOMAB	BLINATUMOMAB		marketed		CD19, CD3	2014-01-01
Blincyto	blinatumomab	Amgen	marketed	Bispecific CD19-directed CD3-directed T Cell Engager	B-lymphocyte antigen CD19	2014-01-01
UPLIZNA	INEBILIZUMAB-CDON	VIELA BIO	marketed	CD19-directed Cytolytic Antibody [EPC]	Low affinity immunoglobulin gamma Fc region receptor III-A, B-lymphocyte antigen CD19
REZ	REZ	Centers for Disease Control and Prevention	marketed	Monoclonal antibody	CD19
IL-2 pre-treated CD19 cells	IL-2 pre-treated CD19 cells	jiangjingting	marketed	Adoptive cell therapy	CD19

Recent regulatory actions (last 90 days)

2026-02-20 — LONCASTUXIMAB TESIRINE · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibody-Drug Conjugate (ADC) class)

· 1 drug in this class
SEAGEN · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LONCASTUXIMAB TESIRINE — Competitive Intelligence Brief. https://druglandscape.com/ci/loncastuximab-tesirine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab